Previous observations have indicated that TGF-β2 concentration is significantly higher in patients with either open-angle glaucoma (OAG) or POAG 11, which mark TGF-β2 as a novel therapeutic target for POAG. The gene discussed is TGFB2; the disease is open-angle glaucoma.